Rentokil Initial PLC
✦ Quant Fair Value how this is computed
- Implied fair-value range of 24.38-41.02, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -26.8% below the average-multiple fair value of 32.70.
Valuation each multiple against its own 5-year range
Vs. peers Specialty Business Services
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Rentokil Initial PLC (RTO) | 12.02B | 25.40 | 2.18 | 2.59% |
| Cintas (CTAS) | 87.36B | 43.39 | 16.79 | 0.85% |
| RELX PLC (RELX) | 66.86B | 23.66 | 41.26 | 2.30% |
| Thomson Reuters (TRI) | 44.02B | 28.04 | 3.92 | 2.54% |
| Copart (CPRT) | 28.80B | 20.06 | 3.17 | 0.00% |
| Global Payments (GPN) | 24.30B | -19.71 | 1.05 | 1.09% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 42.0% below Morningstar's fair value estimate.
Analyst note
Rentokil reported 3.4% organic growth, with North America contributing 3.2%. Management confirmed guidance, expecting profits in line with market expectations, and announced a $200 million share buyback. Both contributed to an 8% rise in shares in early trading Oct. 22.
Why it matters: Rentokil continues to see organic revenue recover after weakness from its Terminix acquisition, with pest control organic revenue expanding 2.4%. Pricing is driving the increase, with volumes still negative but improving. Underlying metrics are improving. Customer retention rose to 81.1%, from 80.9% a year ago, and colleague retention rose to 82.8%, from 81.8%. Residential lead flow fell mid to high single digits in July and August, then improved to about a 1% decline in September. Management said October is broadly similar to September, a sign of positive momentum.
The bottom line: We maintain our fair value estimates of GBX 510 and USD 34 per share for narrow-moat Rentokil. Shares are undervalued despite Oct. 22's increase. We are in line with the market and management-confirmed guidance, anticipating a continued recovery of organic revenue growth in North America. The USD 200 million share buyback came as a positive surprise to investors, funded by deleveraging and proceeds from the sale of SOLitude.
For a deep dive into the moats and valuations of Rentokil and peer Rollins, see our Dec. 8, 2025, report, "Exterminator’s Postacquisition Rebuilding Has Moaty Potential."
Fair value
We are lowering our fair value estimate to $34 per share as management revealed weak North American demand, a restructuring of its North American business, and the removal of its 20% North American margin target, corresponding to a forward enterprise value/EBITDA multiple of 15.1 times 2026 EBITDA of $1.3 billion.
We anticipate Rentokil’s organic revenue to increase over the first five years of our forecast from low current levels as the firm integrates Terminix into its North American business and resolves customer and employee retention issues, which led to poor sales lead development and execution over the past three years. Over the second half of our investment period, we anticipate 5% organic revenue growth and an additional 1.5% from acquisitions. Industry tailwinds, such as rising global temperatures prolonging pest season and greater attention to and investment in health and safety since the pandemic, will aid in this growth.
We forecast margins to increase relative to historical levels, especially in the few years following integration, from 2027 to 2030. The Terminix acquisition materially increases Rentokil’s route density, making each additional new customer margin-accretive in denser areas. We forecast North American adjusted operating margins to expand but at a lower rate than previously guided, given additional investments in organic growth. We believe our margin forecasts lean conservative, given the potential upside from accelerated scale or operating efficiencies gained via restructuring.
Economic moat
We assign Rentokil a narrow Morningstar Economic Moat Rating due to its cost advantage from scale in operations and route density. Poor operational performance in the wake of the Terminix acquisition and lack of brand intangible assets keep it from earning a wide moat like its peer, Rollins.
Rentokil’s largest business, pest control, helps stop pests, including rodents, termites, bedbugs, cockroaches, ants, wasps, and more, for residential and commercial customers. Rentokil also has a hygiene and well-being business (15% of revenue), which we rate as having no moat.
Rentokil and Rollins dominate the pest control industry in the United States, holding 30% and 24% market share of the top 100 pest control firms, respectively. Rentokil complements organic growth with bolt-on acquisitions to maintain its scale advantage; it completed 36 in 2025.
Many costs are primarily incurred at the local level, so an extensive nationwide footprint alone does little to reduce them. To take advantage of scale in servicing, national pest-control companies must have regional scale in each market they operate in. There is a fine line between too few branches, which leads to lost sales, and too many branches, which leads to weaker margins. Evidence suggests that both firms walk this line more effectively than the average pest-control firm, matching their branch density to demand, allowing each technician to serve more clients, reducing unit costs per customer serviced relative to the industry average, thereby increasing revenue per location and revenue per employee.
Scale is also advantageous given the pest-control industry’s high fixed costs, which have accounted for 70%-80 % of total cash operating costs over the past three years. This gives both an advantage over smaller local peers, as they can spread high fixed costs—such as sales and marketing, training, and IT and back-end services—across a larger revenue base, thereby reducing the per-unit price.
Rentokil’s network of local branches constitutes a formidable barrier to entry. A regional pest control firm would need time and capital to replicate Rentokil's footprint and achieve comparable unit costs. For example, a business would need to acquire the next eight largest North American pest control firms to reach Rentokil's size. An existing firm with deep pockets and national scale in a related area seeking to enter the pest control market would require substantial investment to build a network that could rival Rentokil’s.
Rentokil had ROICs above the cost of capital prior to the last three years and shares many similarities with wide-moat peer Rollins. Based on available data and estimates, localized costs related to route density, such as employee, fleet, and property costs, are similar, indicating that both firms benefit from economies of scale. Rentokil also substantially strengthened its cost-advantage moat in North America through the acquisition of Terminix. Despite early struggles with sales execution, this has already led to higher margins, and many of the synergy efforts remain incomplete.
However, due to struggles integrating Terminix and its position relative to Rollins, we do not award Rentokil a wide moat. Rollins and Rentokil’s margins began to diverge after the launch of Rollins’ Boss system, which improves back-end efficiency and route optimization. The system is a key component of Rollins’s almost 7-percentage-point increase in operating margin over the past 15 years. Rentokil has failed to leverage its scale equally, with its margin increasing by 2 percentage points over the same period. Rentokil’s new CEO Mike Duffy has instituted a restructuring plan to close this operational gap over the next few years by implementing global best practices.
Also, we do not believe Rentokil benefits from a brand advantage like its peer, Rollins. Rentokil and its leading North American brand, Terminix, have strong brand recognition and total brand awareness comparable to Rollins’ leading brand, Orkin. Risk aversion is another factor driving consumers to well-known brands, especially in commercials. The perceived downside risk of untested products makes brand recognition highly influential in purchasing decisions and helps maintain strong pricing power.
However, Rentokil has not shown that it can capitalize on its strong brand awareness. Orkin is priced either the same as or slightly above Terminix. Furthermore, Orkin leverages its leading awareness, with 50% of new Orkin clients not considering a competitor when purchasing. Rentokil does not see similar behavior in its clients, evidenced by its sales struggles after the acquisition. While Rentokil achieves higher margins than the industry average, it has trailed Rollins by 5 percentage points over the past decade. This makes us hesitant to award a moat to intangible assets in pest control.
While Rentokil’s hygiene and wellness business shares some moaty characteristics with the pest business, we do not believe it earns a cost advantage moat.
Bull case
The Terminix acquisition bolsters Rentokil’s cost advantage from route density and offers higher margin potential after the integration.
Rentokil can continue to grow following the Terminix acquisition, as half of the industry comprises smaller businesses generating revenue of under $50 million.
Market drivers such as a greater awareness of public health following covid and rising urbanization provide tailwinds for durable organic growth.
Bear case
As the industry consolidates, deal multiples could rise on the 40-50 acquisitions that Rentokil completes a year, harming return on invested capital.
Rentokil has struggled to integrate its Terminix acquisition, and continued issues with sales generation will diminish its route density advantage.
The hygiene and workwear businesses do not contribute to the cost advantage moat, weighing on ROICs.
By Ben Slupecki, CFA
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Rentokil Initial PLC discussion 0 comments